NCT02513888

Brief Summary

PREVENT-WIN study has three components. The work plan will have the following S\&T components. Component 1: Cross-sectional Study Cross-sectional study will be of 1.5 years where 400 women from rural will be screened randomly for the vitamin D deficiency and its determinants including duration of sun exposure. Component 2: Prospective Study This open-label randomized placebo-controlled trial would be done in 150 pre-diabetic women with vitamin D deficiency. The women will be recruited from cross-sectional study, out patient department and health camps and they will be followed up for 2 years. The women will be randomized into two groups; lifestyle modification counseling along with intervention with either vitamin D or placebo. The levels of vitamin D and blood glucose will be assessed periodically (every 6 months). In those having recurrent vitamin D deficiency, the course of vitamin D will be repeated. At the end of the study, incidence of T2DM in both groups will be compared. Component 3: Information Education and Communication (IEC) Activities: There is a paucity of IEC material on vitamin D deficiency in women residing in rural areas. IEC material will be developed and IEC activities through various modes like lectures, workshops, group discussions, leaflets/booklets distribution and audio video media shows (Hindi and English) will be used for educating health professionals, Medical and paramedical workers and various village level health functionaries like, Multi purpose workers, anganwadi workers, Accredited Social Health Activist under National Rural Health Mission of Government of India (ASHA). Besides this, Self Help Groups (SHGs) and women will be told about the benefits of balance diet, dietary intake of calcium, vitamin D, benefits of sun exposure and adverse health effects of vitamin D deficiency.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
121

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2013

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

July 29, 2015

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 3, 2015

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2017

Completed
Last Updated

June 27, 2023

Status Verified

July 1, 2018

Enrollment Period

4.9 years

First QC Date

July 29, 2015

Last Update Submit

June 24, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • fasting glucose (mg/dL)

    2 years

Secondary Outcomes (1)

  • TC (mg/dL)

    2 years

Study Arms (2)

Vitamin D + diet and lifestyle

EXPERIMENTAL

subjects will be given vitamin D supplement will be given along with diet nd lifestyle modification

Dietary Supplement: vitamin D + diet and lifestyle

placebo + diet and lifestyle

PLACEBO COMPARATOR

Subjects will be given placebo with diet and lifestyle

Dietary Supplement: Placebo + diet and lifestyle

Interventions

subjects will be given vitamin D along with diet and lifestyle modification counselling

Vitamin D + diet and lifestyle

placebo along with diet and lifestyle modification counselling

placebo + diet and lifestyle

Eligibility Criteria

Age20 Years - 60 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • \. Prediabetes:
  • Fasting blood glucose ≥100mg/dl and \<126mg/dl, or
  • h plasma glucose ≥140mg/dl and \<200mg/dl (after ingestion of 75 g anhydrous oral glucose), and 2. Baseline level of 25 hydroxy vitamin D \<30ng/dl. 3. Women aged 20-60 years

You may not qualify if:

  • Received Vitamin D and/or calcium supplementation in the previous six months.
  • On any medication within last one month which could potentially influence insulin secretion, insulin sensitivity, vitamin D or calcium metabolism (eg metformin, thiazolidione, steroids etc) and on any medication that activate steroid and xenobiotic receptor and drugs used in transplantation (e.g. steriods, calcitonin etc.)
  • Pregnancy and lactation at the time of study.
  • Severe end organ damage or chronic diseases: renal/ hepatic failure, any malignancy, nephrotic syndrome, malabsorption etc.
  • Known case of HIV infection.
  • Primary or tertiary hyperparathyroidism, granulomatous disorders (e.g. sarcoidosis) and any lymphomas
  • Known case of diabetes mellitus. -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Comprehensive Rural Health Services Project, AIIMS

Ballabgarh, Haryana, 121004, India

Location

Related Publications (1)

  • Misra P, Kant S, Misra A, Jha S, Kardam P, Thakur N, Bhatt SP. A Community Based Randomized Controlled Trial to See the Effect of Vitamin D Supplementation on Development of Diabetes Among Women with Prediabetes Residing in A Rural Community of Northern India. J Family Med Prim Care. 2021 Aug;10(8):3122-3129. doi: 10.4103/jfmpc.jfmpc_311_21. Epub 2021 Aug 27.

MeSH Terms

Conditions

Prediabetic State

Interventions

Vitamin DDiet

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

SecosteroidsSteroidsFused-Ring CompoundsPolycyclic CompoundsNutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Study Officials

  • Puneet Misra, MD

    All India Institute of Medical Sciences, New Delhi, India

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Investigator

Study Record Dates

First Submitted

July 29, 2015

First Posted

August 3, 2015

Study Start

February 1, 2013

Primary Completion

December 31, 2017

Study Completion

December 31, 2017

Last Updated

June 27, 2023

Record last verified: 2018-07

Locations